EP0751960A4 - Synthetic inverso or retro-inverso t-cell epitopes - Google Patents

Synthetic inverso or retro-inverso t-cell epitopes

Info

Publication number
EP0751960A4
EP0751960A4 EP95910335A EP95910335A EP0751960A4 EP 0751960 A4 EP0751960 A4 EP 0751960A4 EP 95910335 A EP95910335 A EP 95910335A EP 95910335 A EP95910335 A EP 95910335A EP 0751960 A4 EP0751960 A4 EP 0751960A4
Authority
EP
European Patent Office
Prior art keywords
inverso
retro
synthetic
cell epitopes
epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95910335A
Other languages
German (de)
French (fr)
Other versions
EP0751960A1 (en
Inventor
Alfio Comis
Margaret Isabel Tyler
Peter Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deakin Research Pty Ltd
Original Assignee
Deakin Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deakin Research Pty Ltd filed Critical Deakin Research Pty Ltd
Publication of EP0751960A1 publication Critical patent/EP0751960A1/en
Publication of EP0751960A4 publication Critical patent/EP0751960A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP95910335A 1994-02-25 1995-02-24 Synthetic inverso or retro-inverso t-cell epitopes Withdrawn EP0751960A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPM4119A AUPM411994A0 (en) 1994-02-25 1994-02-25 Epitopes
AUPM4119/94 1994-02-25
PCT/AU1995/000090 WO1995023166A1 (en) 1994-02-25 1995-02-24 Synthetic inverso or retro-inverso t-cell epitopes

Publications (2)

Publication Number Publication Date
EP0751960A1 EP0751960A1 (en) 1997-01-08
EP0751960A4 true EP0751960A4 (en) 1998-04-29

Family

ID=3778735

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95910335A Withdrawn EP0751960A4 (en) 1994-02-25 1995-02-24 Synthetic inverso or retro-inverso t-cell epitopes

Country Status (6)

Country Link
EP (1) EP0751960A4 (en)
JP (1) JPH09509182A (en)
AU (1) AUPM411994A0 (en)
CA (1) CA2183977A1 (en)
WO (1) WO1995023166A1 (en)
ZA (1) ZA951591B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1277057B1 (en) 1995-12-11 1997-11-04 Tecnogen Scpa IMPROVED ANTIGENIC PEPTIDES
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
FR2763071B1 (en) * 1997-05-07 2003-05-16 Centre Nat Rech Scient PEPTIDE ANALOGS AND THEIR USES IN PARTICULAR IN PHARMACEUTICAL COMPOSITIONS AND FOR DIAGNOSIS
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
JP2002500234A (en) * 1998-01-08 2002-01-08 クリフォード ダックワース、ウィリアム Methods and compositions for treating and diagnosing insulin-related diseases
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
KR100879810B1 (en) 2000-02-21 2009-01-22 하. 룬드벡 아크티에셀스카브 Novel method for down-regulation of amyloid
SK287468B6 (en) * 2000-02-21 2010-10-07 H. Lundbeck A/S Use of an animal's autologous A or APP polypeptide, analogue, nucleic acid fragment, vector, transformed cell, cell line and compositions
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PE20050627A1 (en) 2003-05-30 2005-08-10 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
GB0520068D0 (en) * 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PL2182983T3 (en) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN104744564B (en) 2015-03-13 2017-07-28 天津托普泰克生物科技有限公司 Anti-hepatitis B virus X protein polypeptide drugs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282891A2 (en) * 1987-03-19 1988-09-21 ENIRICERCHE S.p.A. New thymopentin retro-inverso analogs and fragments thereof, a process of preparation of the new compounds and the intermediates obtained therein
WO1991013909A1 (en) * 1990-03-15 1991-09-19 Proteus Molecular Design Limited Synthetic polypeptides
WO1993011155A1 (en) * 1991-12-03 1993-06-10 Proteus Molecular Design Limited Fragments of prion proteins
WO1993021218A1 (en) * 1992-04-16 1993-10-28 Proteus Molecular Design Limited Synthetic polypeptides derived from the hiv envelope glycoprotein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE258188T1 (en) * 1992-08-27 2004-02-15 Deakin Res Ltd RETRO, INVERSO, AND RETRO-INVERSO SYNTHETIC PEPTIDE ANALOGS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282891A2 (en) * 1987-03-19 1988-09-21 ENIRICERCHE S.p.A. New thymopentin retro-inverso analogs and fragments thereof, a process of preparation of the new compounds and the intermediates obtained therein
WO1991013909A1 (en) * 1990-03-15 1991-09-19 Proteus Molecular Design Limited Synthetic polypeptides
WO1993011155A1 (en) * 1991-12-03 1993-06-10 Proteus Molecular Design Limited Fragments of prion proteins
WO1993021218A1 (en) * 1992-04-16 1993-10-28 Proteus Molecular Design Limited Synthetic polypeptides derived from the hiv envelope glycoprotein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
G. GUICHARD ET AL.: "Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, October 1994 (1994-10-01), WASHINGTON US, pages 9765 - 9769, XP002054075 *
See also references of WO9523166A1 *

Also Published As

Publication number Publication date
CA2183977A1 (en) 1995-08-31
WO1995023166A1 (en) 1995-08-31
AUPM411994A0 (en) 1994-03-24
EP0751960A1 (en) 1997-01-08
ZA951591B (en) 1995-12-08
JPH09509182A (en) 1997-09-16

Similar Documents

Publication Publication Date Title
EP0751960A4 (en) Synthetic inverso or retro-inverso t-cell epitopes
GB9619232D0 (en) Cytotoxic T-cell epitopes
EP0448099A3 (en) Novel peptides
PL318017A1 (en) Peptides
CA2049534C (en) Hose cover
GB9111291D0 (en) Diagnostic peptides
EP0746565A4 (en) Novel bombesin-related peptides
GB9114936D0 (en) Seat cover
GB9016810D0 (en) Peptides
GB9425380D0 (en) Peptides
GB9413751D0 (en) Immunodominant peptides
EP0521918A4 (en) Anti-tumour peptides
GB9519779D0 (en) Filing instrument
ZA978027B (en) The use of muramyl peptides
GB9425381D0 (en) Peptides
HK1013148A1 (en) Teremp fabric
GB9021439D0 (en) Improved clamp
GB9411466D0 (en) Zip up quilt cover
GB9028140D0 (en) Peptides
ZA917211B (en) File cover
GB9305136D0 (en) Improved upholstery fabric
GB9025751D0 (en) Pushdry invention
AU122134S (en) Fabric
AU127643S (en) Fabric
GB9410324D0 (en) Fabric

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960919

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 960919;SI PAYMENT 960919

A4 Supplementary search report drawn up and despatched

Effective date: 19980311

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000901